Online inquiry

IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4591MR)

This product GTTS-WQ4591MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD40LG gene. The antibody can be applied in Inflammatory diseases research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000074.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 959
UniProt ID P29965
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ4591MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10917MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ11451MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ9446MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IPH4102
GTTS-WQ3568MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ7994MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ12233MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ5141MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAN-04
GTTS-WQ9153MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMGN-289
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW